BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/25/2023 11:32:55 PM | Browse: 400 | Download: 1123
Publication Name World Journal of Clinical Cases
Manuscript ID 83329
Country Italy
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors
Manuscript Source Invited Manuscript
All Author List Federica Crispino, Andrea Michielan, Mauro Grova, Chiara Tieppo, Marta Mazza, Teresa Marzia Rogger and Franco Armelao
ORCID
Author(s) ORCID Number
Federica Crispino http://orcid.org/0000-0001-7643-3775
Andrea Michielan http://orcid.org/0000-0003-1353-0935
Mauro Grova http://orcid.org/0000-0001-8978-8604
Chiara Tieppo http://orcid.org/0000-0001-5805-7892
Marta Mazza http://orcid.org/0000-0002-8231-8789
Teresa Marzia Rogger http://orcid.org/0000-0002-0395-4219
Franco Armelao http://orcid.org/0000-0003-4307-9479
Funding Agency and Grant Number
Corresponding Author Andrea Michielan, MD, Doctor, Doctor, Gastroenterology and Digestive Endoscopy Unit, Department of Surgery, Santa Chiara Hospital, Azienda Provinciale per i Sevizi Sanitari, Largo Medaglie d’oro 9, Trento 38122, Italy. andrea.michielan@apss.tn.it
Key Words Exit strategy; Biologic withdrawal; Drug holiday; Vedolizumab; Ustekinumab; Tofacitinib
Core Tip Clinicians are still uncertain about whether and when to consider stopping conventional therapies in inflammatory bowel disease (IBD) for fear of disease relapse. Our review aims to shed light on the optimal discontinuation strategies for biologics and the small molecule tofacitinib in IBD.
Publish Date 2023-04-25 23:32
Citation Crispino F, Michielan A, Grova M, Tieppo C, Mazza M, Rogger TM, Armelao F. Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors. World J Clin Cases 2023; 11(12): 2657-2669
URL https://www.wjgnet.com/2307-8960/full/v11/i12/2657.htm
DOI https://dx.doi.org/10.12998/wjcc.v11.i12.2657
Full Article (PDF) WJCC-11-2657.pdf
Full Article (Word) WJCC-11-2657.docx